China is 46% of Axcelis's quarterly revenue and holds the last approval on its $4.4 billion Veeco merger

Axcelis Technologies▲+10.27% — Axcelis Technologies, up 10.27 percent today, the Massachusetts maker of ion-implantation machines for chip factories, earned a demand recovery this quarter, then handed the timing of the payoff to Beijing. Third-quarter bookings jumped by half to $222 million, the strongest since late 2023 ¹. The backlog exited the quarter at $531 million ¹.

The number that matters more came from interim finance chief David Ryzhik on the earnings call: China was 46% of quarterly revenue, with system bookings close behind ². The company's 10-Q↗, the quarterly report it files with the US Securities and Exchange Commission, says antitrust clearance from China's regulator, SAMR, is the only approval still outstanding on its $4.4 billion all-stock purchase of Veeco Instruments, the Nasdaq-listed chip-equipment maker ³⁴⁵.

The AI buildout has reached the implant step

The demand is real, and the chain runs forward from the data center. AI facilities need power conversion from the grid to the rack, plus dense supporting chips; such mature-node devices took 78% of Axcelis's own system shipments this quarter ⁶. Every chip starts on a wafer that passes through ion implantation, the step that fires dopants into silicon to set its electrical properties, and implanters are all Axcelis has sold for more than four decades ⁴.

Chief executive Russell Low tied the North American bookings jump to data-center spillover↗, power bookings have risen four straight quarters, and 2026 will be Axcelis's best year for DRAM, the workhorse memory chips, topping its $90 million record ².

The beat underneath is thinner than the headline

Non-GAAP gross margin printed at 41.2% against a 43% outlook, cut by a sharply stronger Korean won ¹. About $0.30 of the $0.45 GAAP earnings beat came from tax-audit items rather than the factory floor, which is why the fourth-quarter GAAP guide of $1.15 sits below the $1.21 just reported ⁴⁷. Nine-month operating cash flow fell to $77 million from $125 million a year earlier, with about $20 million of Veeco▲+11.79% — Veeco, up 11.79 percent today deal costs inside the accounts ³⁴.

One regulator now decides both stories

If SAMR clears, each Veeco share converts into a fixed 0.3575 Axcelis shares↗ ⁵. Axcelis holders would own about 58% of a company that adds Veeco's laser annealing, advanced packaging and other process lines: revenue not tied to one step and one geography ⁴.

If SAMR refuses, Veeco holders keep their company, while Axcelis holders keep $615 million of cash and the backlog↗ but no second engine ¹. Low told analysts China is developing its own domestic implant supply, which turns the concentration from geographic to strategic ². B. Riley cut its target to $140 from $165↗ on November 6 and kept its buy rating ⁸. The shares closed at $99.24 ⁸.

Half the revenue and the whole merger sit in the same pair of hands. Three things decide what happens next: SAMR's ruling ³, the fresh US antitrust submission the companies plan to make once their current clearance lapses ⁵, and whether the guided $275 million fourth quarter holds its roughly 42.5% margin against the won↗ ¹.